{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:58Z","timestamp":1761057538872,"version":"3.40.4"},"reference-count":3,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2001]]},"abstract":"<i>Background:<\/i> In vitro studies of cefditoren activity have focused primarily on <i>Streptococcus pneumoniae<\/i> and other bacterial species isolated from patients with respiratory infections, but relatively few reports have been published describing the activity of cefditoren against clinical isolates of nonpneumococcal streptococci. <i>Methods:<\/i> Cefditoren activity was determined by broth microdilution (M7-A5, NCCLS, 2000) for 450 viridans group streptococci, 917 <i>Streptococcus pyogenes<\/i> and 800 other \u03b2-hemolytic streptococci collected throughout the US during 1999\u20132000. <i>Results:<\/i> Against viridans group streptococci, cefditoren (MIC<sub>90<\/sub>, 0.5 \u00b5g\/ml) was 4- to 32-fold more active than the other \u03b2-lactams tested (penicillin ampicillin, amoxicillin-clavulanate, cefprozil and cefuroxime). The difference in activity between cefditoren and the other \u03b2-lactams was greater for penicillin-nonsusceptible isolates (MIC<sub>90s<\/sub>, 1 \u00b5g\/ml versus 8\u201332 \u00b5g\/ml) than among penicillin-susceptible isolates (MIC<sub>90s<\/sub>, 0.12 versus 0.25\u2013 1 \u00b5g\/ml). Cefditoren also demonstrated potent activity against <i>S. pyogenes<\/i> (MIC<sub>90<\/sub>, 0.015 \u00b5g\/ml) and other \u03b2-hemolytic streptococci (MIC<sub>90<\/sub>, 0.06 \u00b5g\/ml), comparable to that of the other \u03b2-lactams. <i>Conclusions:<\/i> The activity demonstrated by cefditoren against nonpneumococcal streptococci, including \u03b2-lactam- and macrolide-resistant isolates, suggests that this agent holds promise as therapy for infections caused by all clinically significant species of streptococci.<\/jats:p>","DOI":"10.1159\/000048540","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T13:07:10Z","timestamp":1050412030000},"page":"332-343","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Activity of Cefditoren and Other Oral \u03b2-Lactams against Nonpneumococcal Streptococci"],"prefix":"10.1159","volume":"47","author":[{"given":"C.","family":"Thornsberry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.","family":"Draghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.A.","family":"Critchley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2001,9,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1838-1841.2000"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(91)90068-Q"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1453-1457.2000"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:04:55Z","timestamp":1745467495000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000048540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":3,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000048540","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2001]]}}}